HomeVideoViaCyte ARM CGMOM 2016

ViaCyte ARM CGMOM 2016



President and CEO of ViaCyte, Dr. Paul Laikind, provides an update on ViaCyte’s two product candidates, PEC-Direct and PEC-Encap, which are novel cell replacement therapies being developed as potential long-term type 1 diabetes treatments to reduce the risk of hypoglycemia and diabetes-related complications. This talk was presented at the 2016 Cell and Gene Meeting on the Mesa.

source

Previous post
How does sleep effect your risk of developing diabetes
Next post
Arthritis & Diabetes. Testimonials

Leave a Reply

Be the First to Comment!

Notify of
avatar
wpDiscuz